BR112015009936A8 - uso de uma dose de formulação; bremelanotide para uso em um método para tratar disfunção sexual feminina; e unidade de dose pré-carregada - Google Patents

uso de uma dose de formulação; bremelanotide para uso em um método para tratar disfunção sexual feminina; e unidade de dose pré-carregada Download PDF

Info

Publication number
BR112015009936A8
BR112015009936A8 BR112015009936A BR112015009936A BR112015009936A8 BR 112015009936 A8 BR112015009936 A8 BR 112015009936A8 BR 112015009936 A BR112015009936 A BR 112015009936A BR 112015009936 A BR112015009936 A BR 112015009936A BR 112015009936 A8 BR112015009936 A8 BR 112015009936A8
Authority
BR
Brazil
Prior art keywords
bremelanotide
sexual dysfunction
dose
female sexual
treating female
Prior art date
Application number
BR112015009936A
Other languages
English (en)
Other versions
BR112015009936A2 (pt
Inventor
Spana Carl
D Edelson Jeffrey
Jordan Robert
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015009936(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of BR112015009936A2 publication Critical patent/BR112015009936A2/pt
Publication of BR112015009936A8 publication Critical patent/BR112015009936A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

método para tratar disfunção sexual feminina em uma paciente do sexo feminino diagnosticada com disfunção sexual feminina, mas desejando ter atividade sexual; uso de uma dose de formulação; bremelanotide para uso em um método para tratar disfunção sexual feminina; e unidade de dose pré-carregada trata-se do uso de uma dose administrada por via subcutânea entre cerca de 1,0 mg e 175 mg de bremelanotide ou um sal farmaceuticamente aceitável de bremelanotide para o tratamento de disfunção sexual feminina em mulheres enquanto reduz ou minimiza efeitos colaterais indesejáveis.
BR112015009936A 2012-11-05 2013-11-05 uso de uma dose de formulação; bremelanotide para uso em um método para tratar disfunção sexual feminina; e unidade de dose pré-carregada BR112015009936A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722511P 2012-11-05 2012-11-05
US201361770535P 2013-02-28 2013-02-28
PCT/US2013/068386 WO2014071339A2 (en) 2012-11-05 2013-11-05 Uses of bremelanotide in therapy for female sexual dysfunction

Publications (2)

Publication Number Publication Date
BR112015009936A2 BR112015009936A2 (pt) 2017-07-11
BR112015009936A8 true BR112015009936A8 (pt) 2019-09-17

Family

ID=50628268

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015009936A BR112015009936A8 (pt) 2012-11-05 2013-11-05 uso de uma dose de formulação; bremelanotide para uso em um método para tratar disfunção sexual feminina; e unidade de dose pré-carregada

Country Status (24)

Country Link
US (6) US9352013B2 (pt)
EP (1) EP2916856B2 (pt)
JP (1) JP6567971B2 (pt)
KR (1) KR102253526B1 (pt)
CN (2) CN104755094A (pt)
AU (1) AU2013337341B2 (pt)
BR (1) BR112015009936A8 (pt)
CA (1) CA2890081A1 (pt)
DK (1) DK2916856T4 (pt)
EA (1) EA032959B9 (pt)
ES (1) ES2701444T5 (pt)
FI (1) FI2916856T4 (pt)
GE (1) GEP20196947B (pt)
HK (1) HK1211227A1 (pt)
IL (1) IL238276B (pt)
MX (1) MX362610B (pt)
MY (1) MY179755A (pt)
NZ (1) NZ707246A (pt)
PH (1) PH12015500915B1 (pt)
PL (1) PL2916856T5 (pt)
SG (1) SG11201502949QA (pt)
UA (1) UA118656C2 (pt)
WO (1) WO2014071339A2 (pt)
ZA (1) ZA201503128B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590209B2 (en) * 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
AU2001263766A1 (en) * 2000-05-31 2001-12-11 Novo-Nordisk A/S A disposable double pointed injection needle, and an insulin injection system comprising a disposable double pointed injection needle
CA2453515A1 (en) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
CN101146562B (zh) * 2004-12-09 2011-11-30 韦斯特制药服务公司 自动注射装置的联结器
WO2009120656A1 (en) * 2008-03-24 2009-10-01 Palatin Technologies, Inc. Pharmaceutical for ocular indications
WO2009152079A1 (en) * 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
CN102665401A (zh) * 2009-11-16 2012-09-12 益普生制药股份有限公司 黑皮质素受体配体的药物组合物
RU2695703C2 (ru) * 2010-04-21 2019-07-25 Эббви Байотекнолоджи Лтд. Носимое устройство для автоматической инъекции для управляемой подачи терапевтических агентов

Also Published As

Publication number Publication date
US20220362328A1 (en) 2022-11-17
KR102253526B1 (ko) 2021-05-18
MX2015005486A (es) 2015-11-13
EP2916856A4 (en) 2016-06-22
PH12015500915A1 (en) 2015-06-29
AU2013337341B2 (en) 2018-02-22
CA2890081A1 (en) 2014-05-08
DK2916856T3 (en) 2019-01-14
NZ707246A (en) 2019-03-29
MX362610B (es) 2019-01-28
EP2916856A2 (en) 2015-09-16
AU2013337341A1 (en) 2015-05-07
FI2916856T4 (fi) 2024-01-15
DK2916856T4 (da) 2024-01-22
HK1211227A1 (en) 2016-05-20
EA032959B9 (ru) 2019-11-27
ES2701444T5 (es) 2024-05-21
ES2701444T3 (es) 2019-02-22
EA201590760A1 (ru) 2015-10-30
WO2014071339A3 (en) 2014-06-12
UA118656C2 (uk) 2019-02-25
GEP20196947B (en) 2019-02-11
WO2014071339A2 (en) 2014-05-08
ZA201503128B (en) 2016-11-30
EP2916856B2 (en) 2023-10-18
PL2916856T5 (pl) 2024-01-29
US9352013B2 (en) 2016-05-31
MY179755A (en) 2020-11-12
JP6567971B2 (ja) 2019-08-28
PH12015500915B1 (en) 2015-06-29
EP2916856B1 (en) 2018-09-19
CN104755094A (zh) 2015-07-01
US9700592B2 (en) 2017-07-11
BR112015009936A2 (pt) 2017-07-11
KR20150081345A (ko) 2015-07-13
US20150231196A1 (en) 2015-08-20
IL238276A0 (en) 2015-06-30
IL238276B (en) 2020-04-30
US20210060120A1 (en) 2021-03-04
JP2016503406A (ja) 2016-02-04
EA032959B1 (ru) 2019-08-30
US10286034B2 (en) 2019-05-14
US20180085425A1 (en) 2018-03-29
SG11201502949QA (en) 2015-06-29
PL2916856T3 (pl) 2019-02-28
US20190216888A1 (en) 2019-07-18
US20140378392A1 (en) 2014-12-25
CN117860866A (zh) 2024-04-12

Similar Documents

Publication Publication Date Title
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
NZ602635A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents
MY191040A (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
PE20140872A1 (es) Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
BR112014018485A8 (pt) Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
MX369117B (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
AR080096A1 (es) Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
BR112015009936A2 (pt) método para tratar disfunção sexual feminina em uma paciente do sexo feminino diagnosticada com disfunção sexual feminina, mas desejando ter atividade sexual; uso de uma dose de formulação; bremelanotide para uso em um método para tratar disfunção sexual feminina; e unidade de dose pré-carregada
BR112015012497A2 (pt) combinações farmacêuticas
SI2694065T1 (en) A composition for treating a disorder of hypoactive sexual desire
BR112018002433A2 (pt) composição farmacêutica para tratamento da enxaqueca
Mizuno Antineoplastics/epidermal growth factor inhibitors
Padrnos Budesonide/mycophenolate mofetil/prednisone/tacrolimus
Krivan Antithymocyte globulin/cyclophosphamide
Gokita Non-pigmenting fixed drug eruption: case report

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.